Stockreport

Roivant Sciences Adds Brepocitinib LPP Trial as Batoclimab Misses Phase III TED Endpoint [Yahoo! Finance]

Roivant Sciences Ltd.  (ROIV) 
PDF Phase IIb/III registrational program (72-patient Phase IIb transitioning into ~270-patient Phase III) using an IGA 0/1 primary endpoint and targets an estimated U.S. pat [Read more]